Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
10.64 USD   +0.85%
09:53aBioCryst to Present New ORLADEYO Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
AQ
07:01aBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
02/03BioCryst to Present New ORLADEYO« (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BIOCRYST PHARMACEUTICALS, INC.
09:53aBioCryst to Present New ORLADEYO Data at 2023 American Academy of Allergy, Asthma & Imm..
AQ
07:01aBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
02/03BioCryst to Present New ORLADEYO« (berotralstat) Data at 2023 American Academy of Aller..
AQ
01/26BioCryst Pharmaceuticals Enrolls First Patient in Pediatric Hereditary Angioedema Trial
MT
01/26BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO« (berotralstat) ..
AQ
01/26BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat..
CI
01/24BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO in Central and East..
AQ
01/23BioCryst Pharmaceuticals Signs Agreement With Swixx BioPharma to Market Orladeyo in Cen..
MT
01/23BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO« (berotralstat) in ..
AQ
01/23BioCryst Pharmaceuticals, Inc. Selects Swixx BioPharma as Commercial Partner for ORLADE..
CI
01/10Transcript : BioCryst Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morg..
CI
01/09BioCryst Pharmaceuticals Reports Q4, Full Year 2022 Preliminary ORLADEYO Net Revenue
MT
01/09BioCryst Announces Preliminary Full Year 2022 ORLADEYO« (berotralstat) Net Revenue and ..
AQ
01/09BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting..
AQ
01/09BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibit..
CI
More most relevant news
All news about BIOCRYST PHARMACEUTICALS, INC.
09:53aBioCryst to Present New ORLADEYO Data at 2023 American Academy of Allergy, Asthma & Imm..
AQ
07:01aBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
02/03BioCryst to Present New ORLADEYO« (berotralstat) Data at 2023 American Academy of Aller..
AQ
01/26BioCryst Pharmaceuticals Enrolls First Patient in Pediatric Hereditary Angioedema Trial
MT
01/26BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO« (berotralstat) ..
AQ
01/26BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat..
CI
01/24BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO in Central and East..
AQ
01/23BioCryst Pharmaceuticals Signs Agreement With Swixx BioPharma to Market Orladeyo in Cen..
MT
01/23BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO« (berotralstat) in ..
AQ
01/23BioCryst Pharmaceuticals, Inc. Selects Swixx BioPharma as Commercial Partner for ORLADE..
CI
More news
News in other languages on BIOCRYST PHARMACEUTICALS, INC.
01/26BioCryst Pharmaceuticals enrôle le premier patient d'un essai pédiatrique sur l'angioed..
01/26BioCryst commence le recrutement dans l'essai pivot APeX-P évaluant Orladeyo(R) (Berotr..
01/23BioCryst Pharmaceuticals signe un accord avec Swixx BioPharma pour commercialiser Orlad..
01/23BioCryst Pharmaceuticals, Inc. choisit Swixx BioPharma comme partenaire commercial pour..
01/09BioCryst Pharmaceuticals annonce les recettes nettes préliminaires d'ORLADEYO pour le q..
01/09BioCryst Pharmaceuticals, Inc. annonce les premières données cliniques sur l'inhibiteur..
2022Vente d'initiés : Biocryst Pharmaceuticals
2022BioCryst Pharmaceuticals abandonne le développement d'un médicament contre les maladies..
2022Mise à jour sectorielle : Les actions du secteur de la santé gli..
2022Mise à jour sectorielle : Les actions du secteur de la santé tir..
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
2022Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Pric..
MT
2022RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, ..
MT
2022Oppenheimer Downgrades BioCryst Pharmaceuticals to Perform From Outperform, Removes $13..
MT
2022Barclays Adjusts Price Target on BioCryst Pharmaceuticals to $14 From $12, Keeps Equalw..
MT
2022Evercore ISI Downgrades BioCryst Pharmaceuticals to In-Line From Outperform; Price Targ..
MT
More recommendations
Press releases
09:53aBioCryst to Present New ORLADEYO Data at 2023 American Academy of Allergy, Asthma & Imm..
AQ
07:01aBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
02/03BioCryst to Present New ORLADEYO« (berotralstat) Data at 2023 American Academy of Aller..
AQ
01/26BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO« (berotralstat) ..
AQ
01/24BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO in Central and East..
AQ
More press releases